News

CEO to present at Biotech Showcase 2011

VANCOUVER, B.C. — January 10, 2011 — Allon Therapeutics Inc. (TSX: NPC) President and CEO, Gordon McCauley, will present an update of the Company’s business progress today at 3:30 p.m. PST/ 6:30 p.m. EST at the Biotech Showcase 2011 conference in San Francisco.  The conference is attended by inve... Continue reading →

Allon enrolling patients in pivotal davunetide Phase 2/3 trial

VANCOUVER, B.C. — January 6, 2011 — Allon Therapeutics Inc. (TSX: NPC) announced today that it has initiated a pivotal Phase 2/3 clinical trial to evaluate the Company’s lead neuroprotective drug candidate, davunetide, as a potential treatment for progressive supranuclear palsy (PSP), a rapidly-p... Continue reading →

Allon announces intention to draw down $200,000 from SEDA

VANCOUVER, B.C. — January 5, 2011 — Allon Therapeutics Inc. (TSX: NPC) announced today it has notified YA Global Master SPV Ltd. (“YA”) that it intends to draw down $200,000 under its previously announced $10 million standby equity distribution agreement (SEDA). According to the SEDA provisions, ... Continue reading →

FDA and Allon agree on Special Protocol Assessment for pivotal trial in progressive supranuclear palsy

VANCOUVER, B.C. — January 4, 2011 — Allon Therapeutics Inc. (TSX: NPC) announced today that it has reached agreement with the United States Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for a pivotal Phase 2/3 clinical trial to evaluate the Company’s lead neuroprot... Continue reading →

Allon receives Michael J. Fox Foundation grant for Parkinsons disease research

VANCOUVER, B.C. — November 30, 2010 — Allon Therapeutics Inc. announced today it has received a major grant from the Michael J. Fox Foundation (MJFF) for Parkinson’s Research to conduct pre-clinical research that will help determine the potential of the Company’s lead neuroprotective drug, dav... Continue reading →

← Older posts Newer posts →